Dogwood Therapeutics Email Format

Biotechnology ResearchGeorgia, United States2-10 Employees

Dogwood Therapeutics, based in Alpharetta, Georgia, is a development-stage biotechnology company focused on therapies for pain and neuropathy. Its lead programs include Halneuron, a selective blocker of sodium channels intended to treat chemotherapy-induced neuropathic pain, cancer-associated pain, and related conditions. 

The SP16 program, an LRP1 agonist, is slated to advance into a phase 1b study for chemotherapy-induced neuropathy. Dogwood has entered a licensing agreement with Serpin Pharma to develop and commercialize SP16 for cancer-related pain. The company is also pursuing an intravenous formulation of SP16 and has secured a global license to develop that formulation.

Sign up for free to view info

Company overview Employee directory